In this regard, histamine is being administered as an adjuvant to immunotherapy with IL-2 for the treatment of patients with metastatic melanoma and acute myeloid leukaemia, demonstrating clinical benefits.24,52. This evidence concerns the gene IL2 and acute myeloid leukemia.